Estimating the population prevalence of HPV

JAMA

Volumn 297, Issue 8, 2007, Pages 876-878

  Weller, Susan C ^a   Stanberry, Lawrence R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; CONDYLOMA; DATA ANALYSIS; EDITORIAL; FAMILY PLANNING; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VAGINA SMEAR; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 33847384995     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.8.876     Document Type: Editorial

References (10)

1. Human Papillomavirus Information for Clinicians. http://www.cdc.gov/std/ hpv/common-infection/CDC/HPV_clinicianbro_HR.pdf. Accessed February 1, 2007.
2. HPV and HPV vaccine: information for healthcare providers. http://www.cdc.gov/std/HPV/STDFact-HPV-vaccine-hcp.htm. Accessed January 31, 2007.
3. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
4. Revzina NV, DiClemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005;16:528-537.
5. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(suppl 1):S1-S15.
6. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186:1396-1402.
7. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006;33:502-508.
8. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615.
9. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
10. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001;184:1508-1517.